Teva Pharmaceutical's Ajovy Reduces Migraine Days in Children

MT Newswires Live01-15

Teva Pharmaceutical (TEVA) on late Wednesday said that its drug, Ajovy, significantly reduced monthly migraine and headache days in children and adolescents with episodic migraine phase 3 study, with results published in the New England Journal of Medicine.

According to the company, Ajovy cut monthly migraine days by 2.5 days versus 1.4 days for placebo over 12 weeks, and reduced moderate-to-severe headache days by 2.6 days versus 1.5 days.

Nearly 47% of patients achieved at least a 50% reduction in migraine days, compared with 27% on placebo, the company said.

The data supported the FDA's August 2025 approval of Ajovy for preventive treatment of episodic migraine in children aged 6-17 weighing at least 99 pounds.

Teva said no new safety issues were observed, and the drug's safety profile is consistent with adult studies.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603640435?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-15 06:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603640435","market":"sg","top_or_hot":-1,"title":"Teva Pharmaceutical's Ajovy Reduces Migraine Days in Children","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/TEVA\">Teva</a> Pharmaceutical (TEVA) on late Wednesday said that its drug, Ajovy, significantly reduced monthly migraine and headache days in children and adolescents with episodic migraine phase 3 study, with results published in the <a href=\"https://laohu8.com/S/NEWEN\">New England</a> Journal of Medicine.</p><p>According to the company, Ajovy cut monthly migraine days by 2.5 days versus 1.4 days for placebo over 12 weeks, and reduced moderate-to-severe headache days by 2.6 days versus 1.5 days.</p><p>Nearly 47% of patients achieved at least a 50% reduction in migraine days, compared with 27% on placebo, the company said.</p><p>The data supported the FDA's August 2025 approval of Ajovy for preventive treatment of episodic migraine in children aged 6-17 weighing at least 99 pounds.</p><p>Teva said no new safety issues were observed, and the drug's safety profile is consistent with adult studies.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Teva Pharmaceutical's Ajovy Reduces Migraine Days in Children</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTeva Pharmaceutical's Ajovy Reduces Migraine Days in Children\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-01-15 06:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/TEVA\">Teva</a> Pharmaceutical (TEVA) on late Wednesday said that its drug, Ajovy, significantly reduced monthly migraine and headache days in children and adolescents with episodic migraine phase 3 study, with results published in the <a href=\"https://laohu8.com/S/NEWEN\">New England</a> Journal of Medicine.</p><p>According to the company, Ajovy cut monthly migraine days by 2.5 days versus 1.4 days for placebo over 12 weeks, and reduced moderate-to-severe headache days by 2.6 days versus 1.5 days.</p><p>Nearly 47% of patients achieved at least a 50% reduction in migraine days, compared with 27% on placebo, the company said.</p><p>The data supported the FDA's August 2025 approval of Ajovy for preventive treatment of episodic migraine in children aged 6-17 weighing at least 99 pounds.</p><p>Teva said no new safety issues were observed, and the drug's safety profile is consistent with adult studies.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2603640435","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603640435","pubTimestamp":1768431095,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Teva Pharmaceutical  on late Wednesday said that its drug, Ajovy, significantly reduced monthly migraine and headache days in children and adolescents with episodic migraine phase 3 study, with results published in the New England Journal of Medicine.According to the company, Ajovy cut monthly migraine days by 2.5 days versus 1.4 days for placebo over 12 weeks, and reduced moderate-to-severe headache days by 2.6 days versus 1.5 days.Nearly 47% of patients achieved at least a 50% reduction in migraine days, compared with 27% on placebo, the company said.The data supported the FDA's August 2025 approval of Ajovy for preventive treatment of episodic migraine in children aged 6-17 weighing at least 99 pounds.Teva said no new safety issues were observed, and the drug's safety profile is consistent with adult studies.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","TEVA":"梯瓦制药","BK4557":"大麻股","BK4559":"巴菲特持仓","BK4596":"哈里斯概念","BK4007":"制药","BK4584":"避孕概念","BK4566":"资本集团","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC"},"translate_title":"梯瓦制药的Ajovy减少儿童偏头痛天数","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEVA":1.5},"content_text":"Teva Pharmaceutical (TEVA) on late Wednesday said that its drug, Ajovy, significantly reduced monthly migraine and headache days in children and adolescents with episodic migraine phase 3 study, with results published in the New England Journal of Medicine.According to the company, Ajovy cut monthly migraine days by 2.5 days versus 1.4 days for placebo over 12 weeks, and reduced moderate-to-severe headache days by 2.6 days versus 1.5 days.Nearly 47% of patients achieved at least a 50% reduction in migraine days, compared with 27% on placebo, the company said.The data supported the FDA's August 2025 approval of Ajovy for preventive treatment of episodic migraine in children aged 6-17 weighing at least 99 pounds.Teva said no new safety issues were observed, and the drug's safety profile is consistent with adult studies.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603640435","isCrawlerRequest":true}